Global Demethylation of Rat Chondrosarcoma Cells After Treatment with 5-aza-2'-deoxycytidine Results in Increased Tumorigenicity
Overview
Authors
Affiliations
Abnormal patterns of DNA methylation are observed in several types of human cancer. While localized DNA methylation of CpG islands has been associated with gene silencing, the effect that genome-wide loss of methylation has on tumorigenesis is not completely known. To examine its effect on tumorigenesis, we induced DNA demethylation in a rat model of human chondrosarcoma using 5-aza-2-deoxycytidine. Rat specific pyrosequencing assays were utilized to assess the methylation levels in both LINEs and satellite DNA sequences following 5-aza-2-deoxycytidine treatment. Loss of DNA methylation was accompanied by an increase in invasiveness of the rat chondrosarcoma cells, in vitro, as well as by an increase in tumor growth in vivo. Subsequent microarray analysis provided insight into the gene expression changes that result from 5-aza-2-deoxycytidine induced DNA demethylation. In particular, two genes that may function in tumorigenesis, sox-2 and midkine, were expressed at low levels in control cells but upon 5-aza-2-deoxycytidine treatment these genes became overexpressed. Promoter region DNA analysis revealed that these genes were methylated in control cells but became demethylated following 5-aza-2-deoxycytidine treatment. Following withdrawal of 5-aza-2-deoxycytidine, the rat chondrosarcoma cells reestablished global DNA methylation levels that were comparable to that of control cells. Concurrently, invasiveness of the rat chondrosarcoma cells, in vitro, decreased to a level indistinguishable to that of control cells. Taken together these experiments demonstrate that global DNA hypomethylation induced by 5-aza-2-deoxycytidine may promote specific aspects of tumorigenesis in rat chondrosarcoma cells.
Genetics and Molecular Pathogenesis of the Chondrosarcoma: A Review of the Literature.
Iacobescu G, Corlatescu A, Serban B, Spiridonica R, Costin H, Cirstoiu C Curr Issues Mol Biol. 2024; 46(11):12658-12671.
PMID: 39590345 PMC: 11593320. DOI: 10.3390/cimb46110751.
Molecular predictors for decitabine efficacy in meningiomas - a pilot study.
Spille D, Thomas C, Wagner A, Grauer O, Canisius J, Bunk E J Neurooncol. 2023; 164(1):97-105.
PMID: 37477823 DOI: 10.1007/s11060-023-04379-3.
Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions.
Gilbert A, Tudor M, Montanari J, Commenchail K, Savu D, Lesueur P Cancers (Basel). 2023; 15(7).
PMID: 37046623 PMC: 10093143. DOI: 10.3390/cancers15071962.
Epigenetic Abnormalities in Chondrosarcoma.
Bereza M, Dembinski M, Zajac A, Piatkowski J, Dudzisz-Sledz M, Rutkowski P Int J Mol Sci. 2023; 24(5).
PMID: 36901967 PMC: 10003547. DOI: 10.3390/ijms24054539.
Expression of decitabine-targeted oncogenes in meningiomas in vivo.
Canisius J, Wagner A, Bunk E, Spille D, Stogbauer L, Grauer O Neurosurg Rev. 2022; 45(4):2767-2775.
PMID: 35445910 PMC: 9349086. DOI: 10.1007/s10143-022-01789-1.